GZGuorong Zou

Guorong Zou

*This is an algorithmically generated author record based on publicly available information.

Guorong Zou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 August 2012
      • Vol. 32  (8) , 1171-4

    [Association of serum transforming growth factor-β1 with radiation injury and survival of patients with early-stage nasopharyngeal carcinoma].

    by Guorong Zou, Xiaohui Lin, Jiehong Wu, Jiazhu Hu, Chao Zhang, Jishi Li, Yihua Li, Xiaolong Cao

    To observe the changes in serum transforming growth factor-β1 (TGF-β1) in patients with early-stage nasopharyngeal carcinoma (NPC) after radiotherapy and explore the correlation of serum TGF-β1 with radiation injury and disease-free survival. The average serum TGF-β1 level (50.2∓3.2 ng/ml) determined from 32 healthy volunteers was used as the standard value for NPC patients in this trial. Fifty-seven patients with early-stage (T1-2N0-1M0) NPC without prior treatment were divided into two groups with serum TGF-β1 level before treatment lower than or equal to the standard value (group A, 29 cases) and a level beyond the standard value (group B, 28 cases). Serum TGF-β1 level was determined in all the patients before, during and after the radiotherapy to evaluate the radiation injury and therapeutic effect. The serum TGF-β1 level before radiotherapy was significantly lower in group A than in group B (35.4∓1.4 vs 58.8∓1.0 ng/ml, P0.05). Radiotherapy can significantly decrease serum TGF-β1 level in early NPC patients. Serum TGF-β1 level before radiotherapy can help predict the degree of acute radiation mucositis and skin reaction, but shows no correlation with disease-free survival of early-stage NPC patients.


    • 1 March 2009
      • Vol. 28  (3)

    [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].

    by Fang-Yun Xie, Guo-Rong Zou, Wei-Han Hu, Shu-Nan Qi, Miao Peng, Ji-Shi Li

    Clinical trials on docetaxel plus cisplatin (DDP) (TP regimen) in treating nasopharyngeal carcinoma (NPC) are still uncertain due to limited samples. This study was to compare the short-term efficacy and toxicity of induction chemotherapy with TP regimen followed by concurrent chemoradiotherapy with TP regimen versus DDP in treating locally advanced NPC.


    • 1 August 2007
      • Vol. 26  (8)

    [Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].

    by Fang-Yun Xie, Shu-Nan Qi, Wei-Han Hu, Guo-Rong Zou, Miao Peng, Ji-Shi Li

    Docetaxel and cisplatin (DDP) are effective drugs for head and neck tumors. Stage II-III clinical trial of TP regimen (docetaxel combined DDP) for head and neck tumors has completed. This study was to compare the efficacy and toxicity of TP regimen and PF regimen [DDP combined 5-fluorouracil (5-FU)] in treating nasopharyngeal carcinoma (NPC), to provide a new chemotherapeutic regimen for NPC.